DBVT vs ASMB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ASMB Captures Institutional Edge (2โ2 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Assembly Biosciences, Inc (ASMB) driven by superior Valuation, Growth & Margin while DBVT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DBVT trades at N/M Forward P/E with -5577.0% operating margin (-42.9% YoY revenue) versus ASMB at N/M Forward P/E and -31.8% operating margin (-72.6% YoY). In options structure, DBVT sits in SURGE (13th %ile IV; Dealer Gamma Walls on Pro) against ASMB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DBVT | ASMB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $682.5M | $414.5M | Larger Scale | DBVT |
| Trailing P/E Ratio Valuation | N/M | 19.6x | Lower Multiple | ASMB |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -42.9% | -72.6% | Higher Growth | DBVT |
| Operating Margin (TTM) Profitability | -5577.0% | -31.8% | Higher Margin | ASMB |
| Net Profit Margin Profitability | 0.0% | -16.6% | Higher Margin | DBVT |
| Return on Equity (ROE) Capital Efficiency | -205.8% | -4.6% | Higher ROE | ASMB |
| 52-Week Range Position Momentum | 9% ($9โ$26) | 11% ($19โ$40) | Stronger Trend | ASMB |
| Beta / 30D Volatility Risk Regime | 1.17ฮฒ ยท 77% Vol | 1.08ฮฒ ยท 59% Vol | Lower Realized Risk | ASMB |
| Unified Institutional Score Composite Signal | 30.9 / 100 (SELL) | 42.6 / 100 (HOLD) | Higher Composite | ASMB |